Skip to content
DataLookout
Menu

argenx clinical trial pipeline

Get alerts when argenx's trials change
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-20

What changed in the last 30 days

12 trials changed in the last 30 days: 1 stopped, 3 with notable changes, 8 with minor changes only.

  1. Notable: ADAPT-EARLY · Outcomes of Efgartigimod PH20 SC · New-onset Generalized Myasthenia Gravis (gMG) Primary endpoint(s) modified argenxPhase 4 NCT06909214
  2. Notable: SERENITY · Efgartigimod · Sjogren's Disease-associated Sensorimotor Polyneuropathy or Sensory Polyneuropathy Recruitment opened argenxPhase 2 NCT07760818
  3. Minor: Sparkle · Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy Trial sites expanded: 28 → 46 locations argenxPhase 2 NCT07287982
  4. Minor: ADAPT Forward2 · ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy · AChR-Ab Seropositive Generalized Myasthenia Gravis Trial sites expanded: 14 → 19 locations argenxPhase 2 NCT07673627
  5. Stopped: Correct Dose, Safety and Efficacy of Empasiprubart in Adolescent Participants Aged 12 to Less Than 18 Years With Chronic Inflammatory Demyelinating Polyradiculoneuropathy Withdrawn before enrolling argenxPhase 2/3 NCT07638566
  6. Minor: Empasiprubart · CIDP Trial sites expanded: 89 → 94 locations argenxPhase 3 NCT07091630
  7. Minor: Natural History Study · Congenital Myasthenic Syndromes (CMS) Due to Mutations in DOK7, MUSK, AGRN, or LRP4 Enrollment closed, study ongoing argenxNot specified NCT06078553
  8. Minor: Empasiprubart Versus IVIg · CIDP Trial sites expanded: 101 → 107 locations argenxPhase 3 NCT06920004
  9. Minor: VitaliThy · Efgartigimod PH20 SC PFS · Graves' Disease Trial sites expanded: 32 → 35 locations argenxPhase 3 NCT07570316
  10. Minor: VitaliThy · Efgartigimod PH20 SC PFS · Graves' Disease Trial sites expanded: 42 → 51 locations argenxPhase 3 NCT07596849
  11. Minor: ADAPT Jr · Efgartigimod Administered Intravenously · Generalized Myasthenia Gravis Enrollment closed, study ongoing argenxPhase 2/3 NCT04833894
  12. Notable: Verdant · ARGX-121 on the Change in Proteinuria · IgAN Recruitment opened argenxPhase 2 NCT07773727
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

Active trials by phase

Phase 1
5
Phase 2
13
Phase 2/3
4
Phase 3
12
Phase 4
1
Not charted: 7 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Disease areas by active trials

Get alerts when argenx's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.
Start monitoring free